Such NLC can prevent CLL cell apoptosis in vitro through the release of soluble CXCL12 [8, 22], BAFF or APRIL [23], or indirectly via stimulating the release of CCL3 or CCL4 by B cells [5]. The gene discussed is CXCL12; the disease is B-cell chronic lymphocytic leukemia.